Skip to main content
Erschienen in: Digestive Diseases and Sciences 3/2007

01.03.2007 | Review Paper

The Role of Probiotics in Inflammatory Bowel Disease

verfasst von: Jennifer L. Jones, Amy E. Foxx-Orenstein

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Excerpt

The human intestine contains 300–500 different bacterial species. Concentrations of living bacteria in the large intestine may reach 1011–1012 cells/g of luminal contents [1]. Some of these bacteria are protective, some neutral and others pathogenic [2]. This dynamic community of intestinal microflora plays a critical role in maintaining intestinal health. Metabolic and digestive functions include fermentation of nondigestible dietary residue and mucous, salvage of energy from this residue, production of vitamin K, and absorption of ions. Trophic functions include control of proliferation and differentiation of intestinal epithelial cells, and development and balance of the immune system. These bacteria also protect against pathogens and maintain the epithelial barrier [1]. Probiotics, originally derived from cultured foods and milk products, are viable microorganisms with beneficial physiologic or therapeutic properties [2]. Although the definition of a probiotic has changed many times, a consensus definition term was issued a few years ago. This definition states that “oral probiotics are living microorganisms that, upon ingestion in specific numbers, exert health benefits beyond those of basic nutrition” [3]. Examples of bacteria demonstrated to have beneficial effects include lactic acid bacilli, Lactobacillus, bifidobacterium, Escherichia coli Nissle 1917, Clostridium butyricium, Streptococcus salivarius thermophilus, and a nonpathogenic yeast Saccharomyces boulardii [2, 4]. Mechanisms by which probiotics exert their therapeutic effects include (1) modulation of barrier function, (2) mucosal trophic action, (3) inhibition of pathogenic bacteria, (4) blockade of epithelial attachment and invasion by pathogenic bacteria, (5) modulation of intestinal cytokine production, (6) anti-inflammatory properties, and (7) enhancement of digestion and absorption of food [4, 5]. Properties of an ideal probiotic should include total host safety, resistance to gastric acidity and pancreatic secretions, adherence to epithelial cells, antimicrobial activity, inhibition of pathogenic bacteria, resistance to antibiotics, tolerance to food additives, and stability in food matrix [4]. …
Literatur
1.
Zurück zum Zitat Guarner F, Malagelada J (2003) Gut flora in health and disease.[see comment]. Lancet 361:512–519PubMedCrossRef Guarner F, Malagelada J (2003) Gut flora in health and disease.[see comment]. Lancet 361:512–519PubMedCrossRef
2.
Zurück zum Zitat Sartor R (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126:1620–1633PubMedCrossRef Sartor R (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126:1620–1633PubMedCrossRef
4.
Zurück zum Zitat Fioramonti J, Theodorou V, Bueno L (2003) Probiotics: what are they? What are their effects on gut physiology? Best Pract Res Clin Gastroenterol 17:711–724PubMedCrossRef Fioramonti J, Theodorou V, Bueno L (2003) Probiotics: what are they? What are their effects on gut physiology? Best Pract Res Clin Gastroenterol 17:711–724PubMedCrossRef
5.
Zurück zum Zitat Sartor R (2005) Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol 21:44–50PubMed Sartor R (2005) Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol 21:44–50PubMed
6.
Zurück zum Zitat Donohue D, Salminen S, Marteau P (1998) Safety of probiotic bacteria. In: Salminen S, Von Wright A (eds) Lactic acid bacteria. New York, Marcel Decker, pp 369–384 Donohue D, Salminen S, Marteau P (1998) Safety of probiotic bacteria. In: Salminen S, Von Wright A (eds) Lactic acid bacteria. New York, Marcel Decker, pp 369–384
7.
Zurück zum Zitat Farina C, Arosio M, Mangia M, Moioli F (2001) Lactobacillus casei subsp. rhamnosus sepsis in a patient with ulcerative colitis. J Clin Gastroenterol 33:251–252PubMedCrossRef Farina C, Arosio M, Mangia M, Moioli F (2001) Lactobacillus casei subsp. rhamnosus sepsis in a patient with ulcerative colitis. J Clin Gastroenterol 33:251–252PubMedCrossRef
8.
Zurück zum Zitat Pletinex M, Legein J, Vandeplas Y (1995) Fungicemia with Saccharomyces boulardii in a 1- year old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 21:113–115CrossRef Pletinex M, Legein J, Vandeplas Y (1995) Fungicemia with Saccharomyces boulardii in a 1- year old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 21:113–115CrossRef
9.
Zurück zum Zitat Fedorak R, Madsen K (2004) Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 10:286–299PubMedCrossRef Fedorak R, Madsen K (2004) Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 10:286–299PubMedCrossRef
10.
Zurück zum Zitat Riquelme A, Calvo M, Guzman A, Depix M, Garcia P, Perez C, et al. (2003) Saccharomyses cerevaciae fungemia after Saccharomyses boulardii treatment in immunocompromised patients. J Clin Gastroenterol 36:41–43PubMedCrossRef Riquelme A, Calvo M, Guzman A, Depix M, Garcia P, Perez C, et al. (2003) Saccharomyses cerevaciae fungemia after Saccharomyses boulardii treatment in immunocompromised patients. J Clin Gastroenterol 36:41–43PubMedCrossRef
11.
Zurück zum Zitat Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S, et al. (1999) Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 28:1159–1160PubMed Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S, et al. (1999) Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 28:1159–1160PubMed
12.
Zurück zum Zitat Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard J, Ricour C, Jacquemin J, et al. (2000) Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 19:16–20PubMedCrossRef Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard J, Ricour C, Jacquemin J, et al. (2000) Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 19:16–20PubMedCrossRef
13.
Zurück zum Zitat Tamboli C, Caucheteux C, Cortot A, Colombel J, Desreumaux P (2003) Probiotics in inflammatory bowel disease: a critical review. Best Pract Res Clin Gastroenterol 17:805–820PubMedCrossRef Tamboli C, Caucheteux C, Cortot A, Colombel J, Desreumaux P (2003) Probiotics in inflammatory bowel disease: a critical review. Best Pract Res Clin Gastroenterol 17:805–820PubMedCrossRef
14.
Zurück zum Zitat Salminen M, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, et al. (2002) Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 35:1155–1160PubMedCrossRef Salminen M, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, et al. (2002) Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 35:1155–1160PubMedCrossRef
15.
Zurück zum Zitat Hamilton-Miller J, Shah S, Winkler J (1999) Public health issues arising from microbiological and labelling quality foods and supplements containing probiotic organisms. Public Health Nutr 2:223–229PubMedCrossRef Hamilton-Miller J, Shah S, Winkler J (1999) Public health issues arising from microbiological and labelling quality foods and supplements containing probiotic organisms. Public Health Nutr 2:223–229PubMedCrossRef
16.
Zurück zum Zitat Katz J, Pirovano F, Matteuzzi DEA (2002) Commercially available probiotic preparations: are you getting what you pay for? Gastroenterology 122:A459 Katz J, Pirovano F, Matteuzzi DEA (2002) Commercially available probiotic preparations: are you getting what you pay for? Gastroenterology 122:A459
17.
Zurück zum Zitat Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, zum Meyer Buschenfelde K (1995) Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) [see comment]. Clin Exp Immunol 102:448–455PubMedCrossRef Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, zum Meyer Buschenfelde K (1995) Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) [see comment]. Clin Exp Immunol 102:448–455PubMedCrossRef
18.
Zurück zum Zitat Macpherson A, Khoo U, Forgacs I, Philpott-Howard J, Bjarnason I (1996) Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38:365–375PubMed Macpherson A, Khoo U, Forgacs I, Philpott-Howard J, Bjarnason I (1996) Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38:365–375PubMed
19.
Zurück zum Zitat Sartor R (2003) Microbial influences in inflammatory bowel disease: role in pathogenesis and clinical implications. In: Sartor R, Sandborn W, eds. Kirsner's Inflammatory Bowel Diseases. 6 ed. Edinburgh, Elsevier, pp 138–162 Sartor R (2003) Microbial influences in inflammatory bowel disease: role in pathogenesis and clinical implications. In: Sartor R, Sandborn W, eds. Kirsner's Inflammatory Bowel Diseases. 6 ed. Edinburgh, Elsevier, pp 138–162
20.
Zurück zum Zitat Neut C, Bulois P, Desreumaux P, Membre J, Lederman E, Gambiez L, et al. (2002) Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 97:939–946PubMedCrossRef Neut C, Bulois P, Desreumaux P, Membre J, Lederman E, Gambiez L, et al. (2002) Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 97:939–946PubMedCrossRef
21.
Zurück zum Zitat Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al. (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44–54PubMedCrossRef Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al. (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44–54PubMedCrossRef
22.
Zurück zum Zitat Cartun R, Van Kruiningen H, Pedersen C, Berman M (1993) An immunocytochemical search for infectious agents in Crohn's disease. Modern Pathol 6:212–219 Cartun R, Van Kruiningen H, Pedersen C, Berman M (1993) An immunocytochemical search for infectious agents in Crohn's disease. Modern Pathol 6:212–219
23.
Zurück zum Zitat Shanahan F (2000) Probiotics and inflammatory bowel disease: Is there a scientific rationale? Inflamm Bowel Dis 6:107–115PubMedCrossRef Shanahan F (2000) Probiotics and inflammatory bowel disease: Is there a scientific rationale? Inflamm Bowel Dis 6:107–115PubMedCrossRef
24.
Zurück zum Zitat D’Haens G, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P (1998) Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114:262–267PubMedCrossRef D’Haens G, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P (1998) Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114:262–267PubMedCrossRef
25.
Zurück zum Zitat Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F, Noman M, et al. (2005) Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128:856–861PubMedCrossRef Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F, Noman M, et al. (2005) Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128:856–861PubMedCrossRef
26.
Zurück zum Zitat Cario E (2005) Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 54:1182–1193PubMedCrossRef Cario E (2005) Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 54:1182–1193PubMedCrossRef
27.
Zurück zum Zitat Buning C, Genschel J, Buhner S, Kruger S, Kling K, Dignass A, et al. (2004) Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 19:1073–1078PubMedCrossRef Buning C, Genschel J, Buhner S, Kruger S, Kling K, Dignass A, et al. (2004) Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 19:1073–1078PubMedCrossRef
28.
Zurück zum Zitat Cobrin G, Abreu M (2005) Defects in mucosal immunity leading to Crohn's disease. Immunol Rev 206:277–295PubMedCrossRef Cobrin G, Abreu M (2005) Defects in mucosal immunity leading to Crohn's disease. Immunol Rev 206:277–295PubMedCrossRef
29.
Zurück zum Zitat Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289:1352–1355PubMedCrossRef Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289:1352–1355PubMedCrossRef
30.
Zurück zum Zitat Prantera C, Scribano M, Falasco G, Andreoli A, Luzi C (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 51:405–409PubMedCrossRef Prantera C, Scribano M, Falasco G, Andreoli A, Luzi C (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 51:405–409PubMedCrossRef
31.
Zurück zum Zitat Malchow H (1997) Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 25:653–658 Malchow H (1997) Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 25:653–658
32.
Zurück zum Zitat Guslandi M, Mezzi G, Sorghi M, Testoni P (2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45:1462–1464PubMedCrossRef Guslandi M, Mezzi G, Sorghi M, Testoni P (2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45:1462–1464PubMedCrossRef
33.
Zurück zum Zitat Ingrassia I, Leplingard A, Darfeuille-Michaud A (2005) Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease to and to invade intestinal epithelial cells. Appl Environ Microbiol 71:2880–2887PubMedCrossRef Ingrassia I, Leplingard A, Darfeuille-Michaud A (2005) Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease to and to invade intestinal epithelial cells. Appl Environ Microbiol 71:2880–2887PubMedCrossRef
34.
Zurück zum Zitat Braat H, van den Brande J, van Tol E, Hommes D, Peppelenbosch M, van Deventer S (2004) Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am J Clin Nutr 80:1618–1625PubMed Braat H, van den Brande J, van Tol E, Hommes D, Peppelenbosch M, van Deventer S (2004) Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am J Clin Nutr 80:1618–1625PubMed
35.
Zurück zum Zitat Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. (1999) Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 13:1103–1108PubMedCrossRef Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. (1999) Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 13:1103–1108PubMedCrossRef
36.
Zurück zum Zitat Rembacken B, Snelling A, Hawkey P, Chalmers D, Axon A (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354(9179):635–639PubMedCrossRef Rembacken B, Snelling A, Hawkey P, Chalmers D, Axon A (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354(9179):635–639PubMedCrossRef
37.
Zurück zum Zitat Kruis W, Kalk E, Fric P, et al. (2001) Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine. Gastroenterology 120:A127CrossRef Kruis W, Kalk E, Fric P, et al. (2001) Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine. Gastroenterology 120:A127CrossRef
38.
Zurück zum Zitat Schroeder K, Tremaine W, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis-a randomized study. N Engl J Med 317:1625–1629PubMedCrossRef Schroeder K, Tremaine W, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis-a randomized study. N Engl J Med 317:1625–1629PubMedCrossRef
39.
Zurück zum Zitat Baron J, Connell A, Lennard-Jones J (1964) Variation in observers in describing mucosal appearances in proctocolitis. BMJ i:89–92CrossRef Baron J, Connell A, Lennard-Jones J (1964) Variation in observers in describing mucosal appearances in proctocolitis. BMJ i:89–92CrossRef
40.
Zurück zum Zitat Fedorak R, Gionchetti P, Campieri M (2003) VSL3 probiotic mixture induces remission in patients with active ulcerative colitis (abstr). Gastroenterology 124:A377CrossRef Fedorak R, Gionchetti P, Campieri M (2003) VSL3 probiotic mixture induces remission in patients with active ulcerative colitis (abstr). Gastroenterology 124:A377CrossRef
41.
Zurück zum Zitat Guslandi M, Giollo P, Testoni P (2003) A pilot trial of saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15:697–698PubMedCrossRef Guslandi M, Giollo P, Testoni P (2003) A pilot trial of saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15:697–698PubMedCrossRef
42.
Zurück zum Zitat Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119:305–309PubMedCrossRef Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119:305–309PubMedCrossRef
43.
Zurück zum Zitat Mimura T, Rizzello F, Schreiber S, et al. (2002) Once daily high dose probiotic therapy maintains remission and improved quality of life in patients with recurrent or refractory pouchitis: a randomized, placebo-controlled, double-blind trial. Gastroenterology 122:A81 Mimura T, Rizzello F, Schreiber S, et al. (2002) Once daily high dose probiotic therapy maintains remission and improved quality of life in patients with recurrent or refractory pouchitis: a randomized, placebo-controlled, double-blind trial. Gastroenterology 122:A81
44.
Zurück zum Zitat Sandborn W, Tremaine W, Batts K, Pemberton J, Phillips S (1994) Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc 69:409–415PubMed Sandborn W, Tremaine W, Batts K, Pemberton J, Phillips S (1994) Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc 69:409–415PubMed
45.
Zurück zum Zitat Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers K, Brigidi P, et al. (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124:1202–1209PubMedCrossRef Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers K, Brigidi P, et al. (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124:1202–1209PubMedCrossRef
46.
Zurück zum Zitat Shen B, Fazio V, Remzi F, et al. (2005) An open-labeled trial of probiotic as a maintenance therapy in patients with antibiotic-dependent pouchitis. Gastroenterology 124:A586 Shen B, Fazio V, Remzi F, et al. (2005) An open-labeled trial of probiotic as a maintenance therapy in patients with antibiotic-dependent pouchitis. Gastroenterology 124:A586
47.
Zurück zum Zitat Heuschen U, Autschbach F, Allemeyer E, Zollinger A, Heuschen G, Uehlein T, et al. (2001) Long-term follow-up after ileoanal pouch procedure: algorithm for diagnosis, classification, and management of pouchitis. Dis Colon Rectum 44:487–499PubMedCrossRef Heuschen U, Autschbach F, Allemeyer E, Zollinger A, Heuschen G, Uehlein T, et al. (2001) Long-term follow-up after ileoanal pouch procedure: algorithm for diagnosis, classification, and management of pouchitis. Dis Colon Rectum 44:487–499PubMedCrossRef
48.
Zurück zum Zitat Shen B, Achkar J, Lashner B, Ormsby A, Remzi F, Bevins C, et al. (2001) Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 121:261–267PubMedCrossRef Shen B, Achkar J, Lashner B, Ormsby A, Remzi F, Bevins C, et al. (2001) Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 121:261–267PubMedCrossRef
Metadaten
Titel
The Role of Probiotics in Inflammatory Bowel Disease
verfasst von
Jennifer L. Jones
Amy E. Foxx-Orenstein
Publikationsdatum
01.03.2007
Erschienen in
Digestive Diseases and Sciences / Ausgabe 3/2007
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9225-y

Weitere Artikel der Ausgabe 3/2007

Digestive Diseases and Sciences 3/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.